Barinthus Biotherapeutics (BRNS) Share-based Compensation (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Share-based Compensation came in at $556000.0 in Q1 2026, up 18.8% YoY from $468000.0 in Q1 2025, and down 20.11% on a QoQ basis from $696000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Share-based Compensation (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Share-based Compensation data on file, last reported at $556000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 18.8% year-over-year to $556000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $556000.0 (down 84.39% YoY) and the FY2025 annual result came in at $468000.0, down 90.06% from the prior year.
- Share-based Compensation eased to $556000.0 in Q1 2026, from $696000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $8.7 million in Q3 2022 to a low of -$415000.0 in Q3 2025.
- A 5-year average of $2.0 million and a median of $1.1 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation surged 1907.02% — and 2025, when it tumbled 136.28%.
- Tracing BRNS's Share-based Compensation over 5 years: stood at $7.5 million in 2022, then sank by 89.49% to $786000.0 in 2023, then decreased by 3.94% to $755000.0 in 2024, then fell by 7.81% to $696000.0 in 2025, then fell by 20.11% to $556000.0 in 2026.
- The last three Share-based Compensation figures came in at $556000.0 (Q1 2026), $696000.0 (Q4 2025), and -$415000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Barinthus Biotherapeutics | 25.01 Mn | 25.01 Mn | - | 433,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 433,000.00 |
| Jun 30, 2026 | 433,000.00 |
| Mar 31, 2026 | 556,000.00 |
| Mar 31, 2026 | 556,000.00 |
| Dec 31, 2025 | 696,000.00 |
| Dec 31, 2025 | 696,000.00 |
| Sep 30, 2025 | -415,000.00 |
| Sep 30, 2025 | -415,000.00 |
| Jun 30, 2025 | -281,000.00 |
| Jun 30, 2025 | -281,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Dec 31, 2024 | 755,000.00 |
| Dec 31, 2024 | 755,000.00 |
| Sep 30, 2024 | 1.14 Mn |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.62 Mn |
| Mar 31, 2024 | 1.62 Mn |